Previous 10 | Next 10 |
ALPHARETTA, Ga., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that George Lasezkay, Pharm.D., ...
Clearside Biomedical, Inc. (CLSD) Q3 2022 Earnings Call Transcript November 9, 2022 08:30 a.m. ET Company Representatives George Lasezkay - Chief Executive Officer Tom Ciulla - Chief Medical Officer, Chief Development Officer Charles Deignan - Chief Financial Off...
Stifel has upgraded Clearside Biomedical ( NASDAQ: CLSD ) to buy from hold saying that there is promise for candidate CLS-AX as a next-generation wet age-related macular degeneration treatment. The firm upped its price target to $8 from $7 (~471% upside based on Monday's c...
Clearside Biomedical ( NASDAQ: CLSD ) reported data from a phase 1/2a trial called OASIS of CLS-AX (axitinib injectable suspension) in patients with neovascular age-related macular degeneration (wet AMD), a type of eye disease. The trial results ...
Clearside Biomedical press release ( NASDAQ: CLSD ): Q3 GAAP EPS of -$0.13 beats by $0.01 . Revenue of $0.26M (-91.6% Y/Y) misses by $6.26M . For further details see: Clearside Biomedical GAAP EPS of -$0.13 beats by $0.01, revenue of $0.26M misses by $6.2...
- Favorable Safety Results, Durability and Biologic Effect Observed in Cohorts 3 and 4 of CLS-AX OASIS Phase 1/2a Trial - - Recent Positive Data Presentations Highlight the Potential Safety, Efficacy and Durability Benefits of Suprachoroidal Administration of Small Molecul...
- Primary Safety Endpoint Achieved at all Timepoints with All Doses Well-Tolerated and No Treatment Related or Serious Adverse Events - - Cohorts 3 and 4 Demonstrated Promising Signs of Durability, Biologic Effect, and a Meaningful Reduction in Treatment Burden - - Final 6-Month Dat...
ALPHARETTA, Ga., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that the Company will host a con...
ALPHARETTA, Ga., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that its third quarter 2022 fina...
- Favorable Safety Profiles and Encouraging Efficacy Data Reported in Clinical Trials in the Suprachoroidal Space (SCS ® ) Across Multiple Therapeutic Areas using Clearside’s SCS Microinjector ® - - SCS Microinjector ® Feat...
News, Short Squeeze, Breakout and More Instantly...
Clearside Biomedical Inc. Company Name:
CLSD Stock Symbol:
NASDAQ Market:
Clearside Biomedical Inc. Website:
ALPHARETTA, Ga., July 22, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), has opened registration for its virtual key opinion l...
ALPHARETTA, Ga., July 11, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today the appointment of Glenn C. Yiu, M.D....
- Webinar to be held on Wednesday, July 24, 2024 at 8:00 am ET - - Retina Specialists to Provide Insights and Real-World Experience with Suprachoroidal Drug Delivery - - Target Profile for CLS-AX in Wet AMD Landscape and Potential Opportunities for Clearside Pipeline Expansion - ...